In 2020 the BIEL CEO stated the goal of selling the company and retiring within four years.
Here is how that can actually happen — starting right now.
For four years, that statement has just been a line in an old interview.
Today, for the first time, the conditions exist to make it real.
And the key is simple:
Ken Mayer + Electrome + BIEL’s public‑company status = a clean, executable path to a sale.
1. Mayer’s exit from Electrome unlocks the move that wasn’t possible before
When Mayer reportedly declined the BIEL CEO job (stated in his first investor call a few weeks ago according to Gofer/Gopher) earlier this year, it wasn’t because he didn’t want it.
It was because he couldn’t take it.
He was CEO of Electrome.
Electrome depends on BIEL hardware.
He couldn’t run both sides of the same ecosystem.
Now?
He’s out.
The conflict barrier is gone.
His reputation is intact.
Electrome is shifting to a founder‑led, science‑first model.
This is the first moment where a Mayer = BIEL CEO transition is structurally possible.
2. Mayer’s relationship with Electrome is EXACTLY what enables a sale
Mayer isn’t just “familiar” with BIEL.
He built Electrome’s entire platform on top of BIEL’s hardware.
He validated it.
He integrated it.
He commercialized it.
He knows the tech better than anyone outside BIEL itself.
Now imagine this structure:
Electrome (private) = AI, software, clinical, deep‑tech
BIEL (public) = hardware, manufacturing, distribution, capital markets
Put Mayer at the helm of the public entity and suddenly:
The ecosystem becomes vertically aligned
The valuation becomes scalable
The merger path becomes clean
The exit becomes realistic
This is how real biotech platforms are built before acquisition.
This is how you get to a sale.
3. BIEL being publicly traded is the weapon that makes the exit possible
Electrome is private.
BIEL is public.
If Mayer becomes CEO of BIEL, the public entity becomes:
A capital‑markets engine
for manufacturing scale, distribution, and M&A.
A liquidity pathway
for Electrome investors in a future merger.
A valuation amplifier
because public markets price growth, not just revenue.
A clean acquisition target
because acquirers prefer public entities with transparent cap tables.
This is EXACTLY how you structure a company for a sale.
4. The CEO compensation package that makes Mayer say yes — WITHOUT diluting shareholders
Here is the updated, Musk‑style, performance‑only package:
100M shares for every $0.01 PPS increase, from $0.01 to $0.10
Total potential: 1,000,000,000 shares (1B)
Total dilution today: ZERO
Total cost today: ZERO
He only gets paid if he builds a billion‑dollar company.
How to make it non‑dilutive:
A) Insider Convertible Notes = Reallocation Pool
Insiders give up a tiny percentage of their convertibles.
They still profit massively because PPS appreciation multiplies the value of their remaining notes.
Performance‑Triggered Warrants
Not exercisable today.
Not dilutive today.
Only unlock at PPS milestones.
Cash‑exercise only = brings capital into BIEL.
C) Treasury Shares from a Buyback
If BIEL buys back even a small block, those shares can be held in reserve and transferred to Mayer only when milestones are hit.
5. How this leads directly to a sale
Here’s the exact sequence:
Step 1 — Mayer becomes CEO of BIEL
Commercial operator takes over the public entity.
Step 2 — Electrome + BIEL operate as a synchronized ecosystem
Hardware + AI = unified therapeutic platform.
Step 3 — PPS milestones are hit
VA expansion
CMS channels
3,700‑pharmacy rollout
AI‑driven outcomes data
Institutional visibility
Step 4 — Market cap expands
This is where the Musk‑style package works:
Mayer only gets paid if the valuation explodes.
Step 5 — Ecosystem becomes merger‑ready
Electrome investors gain liquidity.
BIEL shareholders gain scale.
The combined entity becomes uplist‑ready.
Step 6 — Strategic acquirers enter
Med‑tech, AI‑health, or digital therapeutics companies look for:
Proven hardware
Proven AI
Proven outcomes
Public‑company transparency
Scalable margins
This is EXACTLY what they buy.
Step 7 — The 2020 retirement/sale goal becomes real
SUMMARY
In 2020 the BIEL CEO stated the goal of selling the company and retiring within four years.
Here is how that can finally happen.
Ken Mayer is now free to take the CEO role at BIEL.
Electrome is shifting to science.
BIEL is shifting to commercialization.
The conflict barrier is gone.
The timing is perfect.
Mayer’s relationship with Electrome creates a clean path to:
A synchronized hardware + AI ecosystem
A future merger
A scalable valuation
A real acquisition target
A CEO transition that aligns with the 2020 retirement plan
And the compensation package is simple:
100M shares for every $0.01 PPS increase up to $0.10 (1B total).
Zero dilution today.
Zero cost today.
This is how you build a billion‑dollar bioelectronic medicine platform.
This is how you structure a company for a sale.
This is how the 2020 retirement plan becomes reality.
Here is how that can actually happen — starting right now.
For four years, that statement has just been a line in an old interview.
Today, for the first time, the conditions exist to make it real.
And the key is simple:
Ken Mayer + Electrome + BIEL’s public‑company status = a clean, executable path to a sale.
1. Mayer’s exit from Electrome unlocks the move that wasn’t possible before
When Mayer reportedly declined the BIEL CEO job (stated in his first investor call a few weeks ago according to Gofer/Gopher) earlier this year, it wasn’t because he didn’t want it.
It was because he couldn’t take it.
He was CEO of Electrome.
Electrome depends on BIEL hardware.
He couldn’t run both sides of the same ecosystem.
Now?
He’s out.
The conflict barrier is gone.
His reputation is intact.
Electrome is shifting to a founder‑led, science‑first model.
This is the first moment where a Mayer = BIEL CEO transition is structurally possible.
2. Mayer’s relationship with Electrome is EXACTLY what enables a sale
Mayer isn’t just “familiar” with BIEL.
He built Electrome’s entire platform on top of BIEL’s hardware.
He validated it.
He integrated it.
He commercialized it.
He knows the tech better than anyone outside BIEL itself.
Now imagine this structure:
Electrome (private) = AI, software, clinical, deep‑tech
BIEL (public) = hardware, manufacturing, distribution, capital markets
Put Mayer at the helm of the public entity and suddenly:
The ecosystem becomes vertically aligned
The valuation becomes scalable
The merger path becomes clean
The exit becomes realistic
This is how real biotech platforms are built before acquisition.
This is how you get to a sale.
3. BIEL being publicly traded is the weapon that makes the exit possible
Electrome is private.
BIEL is public.
If Mayer becomes CEO of BIEL, the public entity becomes:
A capital‑markets engine
for manufacturing scale, distribution, and M&A.
A liquidity pathway
for Electrome investors in a future merger.
A valuation amplifier
because public markets price growth, not just revenue.
A clean acquisition target
because acquirers prefer public entities with transparent cap tables.
This is EXACTLY how you structure a company for a sale.
4. The CEO compensation package that makes Mayer say yes — WITHOUT diluting shareholders
Here is the updated, Musk‑style, performance‑only package:
100M shares for every $0.01 PPS increase, from $0.01 to $0.10
Total potential: 1,000,000,000 shares (1B)
Total dilution today: ZERO
Total cost today: ZERO
He only gets paid if he builds a billion‑dollar company.
How to make it non‑dilutive:
A) Insider Convertible Notes = Reallocation Pool
Insiders give up a tiny percentage of their convertibles.
They still profit massively because PPS appreciation multiplies the value of their remaining notes.
Performance‑Triggered Warrants Not exercisable today.
Not dilutive today.
Only unlock at PPS milestones.
Cash‑exercise only = brings capital into BIEL.
C) Treasury Shares from a Buyback
If BIEL buys back even a small block, those shares can be held in reserve and transferred to Mayer only when milestones are hit.
5. How this leads directly to a sale
Here’s the exact sequence:
Step 1 — Mayer becomes CEO of BIEL
Commercial operator takes over the public entity.
Step 2 — Electrome + BIEL operate as a synchronized ecosystem
Hardware + AI = unified therapeutic platform.
Step 3 — PPS milestones are hit
VA expansion
CMS channels
3,700‑pharmacy rollout
AI‑driven outcomes data
Institutional visibility
Step 4 — Market cap expands
This is where the Musk‑style package works:
Mayer only gets paid if the valuation explodes.
Step 5 — Ecosystem becomes merger‑ready
Electrome investors gain liquidity.
BIEL shareholders gain scale.
The combined entity becomes uplist‑ready.
Step 6 — Strategic acquirers enter
Med‑tech, AI‑health, or digital therapeutics companies look for:
Proven hardware
Proven AI
Proven outcomes
Public‑company transparency
Scalable margins
This is EXACTLY what they buy.
Step 7 — The 2020 retirement/sale goal becomes real
SUMMARY
In 2020 the BIEL CEO stated the goal of selling the company and retiring within four years.
Here is how that can finally happen.
Ken Mayer is now free to take the CEO role at BIEL.
Electrome is shifting to science.
BIEL is shifting to commercialization.
The conflict barrier is gone.
The timing is perfect.
Mayer’s relationship with Electrome creates a clean path to:
A synchronized hardware + AI ecosystem
A future merger
A scalable valuation
A real acquisition target
A CEO transition that aligns with the 2020 retirement plan
And the compensation package is simple:
100M shares for every $0.01 PPS increase up to $0.10 (1B total).
Zero dilution today.
Zero cost today.
This is how you build a billion‑dollar bioelectronic medicine platform.
This is how you structure a company for a sale.
This is how the 2020 retirement plan becomes reality.
1
